Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Hearing Loss, Sensorineural 1Hearing Loss 1Ear Diseases 1Deafness 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1

Interventions

Peripheral Blood Stem Cell Transplantation 6Methotrexate 4Cyclosporine 4Busulfan 4ruxolitinib 3fludarabine phosphate 2Whole-Body Irradiation 2Mycophenolic Acid 2Flow Cytometry 2Cytogenetic Analysis 2Cyclophosphamide 2Antilymphocyte Serum 2venetoclax 1sonidegib 1pomalidomide 1pevonedistat 1lestaurtinib 1givinostat hydrochloride 1givinostat 1ethanolamine oleate 1aldesleukin 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Tacrolimus 1Sulfamethoxazole 1Stem Cell Transplantation 1Staining and Labeling 1Sodium Chloride 1Saline Solution, Hypertonic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thrombocythemia, Essential × Acetylcysteine × Clear all
NCT05123365 2026-03-10

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

University of California, Irvine

Phase 1/2 Recruiting
27 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡